Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3358629rdf:typepubmed:Citationlld:pubmed
pubmed-article:3358629lifeskim:mentionsumls-concept:C0600139lld:lifeskim
pubmed-article:3358629lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:3358629lifeskim:mentionsumls-concept:C2349101lld:lifeskim
pubmed-article:3358629lifeskim:mentionsumls-concept:C1514863lld:lifeskim
pubmed-article:3358629pubmed:issue1lld:pubmed
pubmed-article:3358629pubmed:dateCreated1988-5-16lld:pubmed
pubmed-article:3358629pubmed:abstractTextThe prognostic significance of the DNA-Malignancy-Grade (DNA-MG) was tested in 52 prostatic carcinoma patients in comparison with a cytomorphological grading system and the clinical staging. Papanicolaou- or MGG stained smears from transrectal aspiration biopsies were automatically restained according to Feulgen in a modified Shandon staining machine. The DNA-MG, based on the variation of the nuclear DNA content of tumor cells around the normal DNA peak, ranges on a continuous scale from 0.01 to 3.0. It was determined with a TV-image analysis system (Leitz, TAS plus), combined with an automatic microscope. The DNA-MG revealed a high prognostic validity, the clinical stage showed only a minor influence on the survival time and the cytopathologic grading system was of insufficient prognostic information. Significant differences in survival time could be demonstrated between patients with DNA-MGs of 0.01-1.5 and 1.5-3.0, as well as with DNA-MGs 1.0-2.0 and 2.0-3.0. The intra- and interobserver variations of the DNA grading system were found to be sigma = 0.014 and sigma = 0.036 respectively. The reproducibilities were 86.7% for intra- and interobserver measurements, when the continuous DNA-MG scale was divided in three groups.lld:pubmed
pubmed-article:3358629pubmed:languageenglld:pubmed
pubmed-article:3358629pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3358629pubmed:citationSubsetIMlld:pubmed
pubmed-article:3358629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3358629pubmed:statusMEDLINElld:pubmed
pubmed-article:3358629pubmed:issn0250-7005lld:pubmed
pubmed-article:3358629pubmed:authorpubmed-author:BöckingAAlld:pubmed
pubmed-article:3358629pubmed:authorpubmed-author:ChatelainRRlld:pubmed
pubmed-article:3358629pubmed:authorpubmed-author:GiecLLlld:pubmed
pubmed-article:3358629pubmed:authorpubmed-author:JochamDDlld:pubmed
pubmed-article:3358629pubmed:authorpubmed-author:von...lld:pubmed
pubmed-article:3358629pubmed:authorpubmed-author:WohltmannDDlld:pubmed
pubmed-article:3358629pubmed:authorpubmed-author:OrthenUUlld:pubmed
pubmed-article:3358629pubmed:issnTypePrintlld:pubmed
pubmed-article:3358629pubmed:volume8lld:pubmed
pubmed-article:3358629pubmed:ownerNLMlld:pubmed
pubmed-article:3358629pubmed:authorsCompleteYlld:pubmed
pubmed-article:3358629pubmed:pagination129-35lld:pubmed
pubmed-article:3358629pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3358629pubmed:meshHeadingpubmed-meshheading:3358629-...lld:pubmed
pubmed-article:3358629pubmed:meshHeadingpubmed-meshheading:3358629-...lld:pubmed
pubmed-article:3358629pubmed:meshHeadingpubmed-meshheading:3358629-...lld:pubmed
pubmed-article:3358629pubmed:meshHeadingpubmed-meshheading:3358629-...lld:pubmed
pubmed-article:3358629pubmed:meshHeadingpubmed-meshheading:3358629-...lld:pubmed
pubmed-article:3358629pubmed:meshHeadingpubmed-meshheading:3358629-...lld:pubmed
pubmed-article:3358629pubmed:meshHeadingpubmed-meshheading:3358629-...lld:pubmed
pubmed-article:3358629pubmed:articleTitleDNA-grading of prostatic carcinoma: prognostic validity and reproducibility.lld:pubmed
pubmed-article:3358629pubmed:affiliationDepartment of Pathology, Aachen University of Technology, F.R.G.lld:pubmed
pubmed-article:3358629pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3358629pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed